Drug factory · FDA FEI 3005343934
Bioreliance Ltd.
Todd Campus Glasgow West of Scotland Science Park, Glasgow Lanarkshire, United Kingdom
Problems found, fixed voluntarily at FDA's last inspection, May 13, 2026.
Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.
7 drug inspections on record since 2009: 2 with no problems, 5 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
| Drug | Role | For | NDC |
|---|---|---|---|
| Aflibercept | Makes it and tests it | CELLTRION USA, Inc., Regeneron Pharmaceuticals, Inc. | 72606-026, 61755-005 |
| Alirocumab | Tests it | Regeneron Pharmaceuticals, Inc. | 61755-020, 61755-021 |
| Apadamtase Alfa | Tests it | Takeda Pharmaceuticals America, Inc. | 64764-140, 64764-145 |
| Cemiplimab | Tests it | Regeneron Pharmaceuticals, Inc. | 61755-008 |
| Hyaluronidase (human Recombinant) and Nivolumab | Tests it | E.R. Squibb & Sons, L.L.C. | 0003-3120, 0003-6120 |
| Tislelizumab | Tests it | BeOne Medicines USA, Inc. | 72579-121, 72579-125 |
| Tocilizumab | Tests it | Biogen MA Inc. | 64406-022, 64406-023 |
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| May 13, 2026 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Mar 17, 2021 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Sep 27, 2019 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Sep 22, 2017 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Jul 16, 2014 | No problems found | Drug Quality Assurance | — |
| Jul 25, 2011 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Jul 2, 2009 | No problems found | Drug Quality Assurance | — |
Registered with FDA for: analysis; manufacture.